Market Overview

UPDATE: Jefferies Downgrades HealthSouth Corporation to Hold on Regulatory Headwinds

Share:
Related HLS
HealthSouth Risk/Reward Profile Grows Worse
7 Largest Price Target Changes For Monday

Jefferies lowered its HealthSouth Corporation (NYSE: HLS) rating from Buy to Hold and reduced its price target from $25 to $23.

Jefferies noted, "HLS's strong Q2 performance and raised guidance was impressive, but we recommend taking advantage of stock strength to lighten long positions, fearing that IRF reimbursement could get greater scrutiny later this year when legislators look for funding offsets to another doc fix and deficit reduction."

HealthSouth Corporation closed at $22.93 on Thursday.

Latest Ratings for HLS

DateFirmActionFromTo
Jun 2016BarclaysDowngradesEqual-weightUnderweight
Oct 2015SunTrust Robinson HumphreyMaintainsBuy
Oct 2015BarclaysMaintainsEqualweight

View More Analyst Ratings for HLS
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (HLS)

View Comments and Join the Discussion!